Construction of a new DNA vaccine based on truncated BAP31 and study on its anti-tumor effects
AIM: To develop an anti-tumor DNA vaccine encoding a truncated protein of routine BAP31 (△BAF31) to en-hance endogenous antigen trafficking to the MHC-Ⅱ compartment of antigen-presenting cells by LAMP and to study its efficacy to induce cellular and humoral immunity. METHODS: The DNA vaccine was identified by restriction enzyme analysis, sequencing and protein expression. The frequency of cells producing IFN-γ or IL-4 in splenocytes immunized mice was measured by ELISPOT. Specific antibodies for △BAP31 were determined by indirect ELISA and cytotoxicity of specific CTL was measured by LDH releasing assay. RESULTS : ELISPOT showed that the number of IFN-γ and IL-4-producing cells in LAMP group was significantly higher than that in control groups. The level of △BAP31 specific antibodies and CTL the cytotoxicity in LAMP group were markedly higher than those in control groups. CONCLUSION: LAMP enhances cellular and humoral response through greater antigen-specific activation of both CD4+ T cells and CD8+ T cells.
NETL
NSTL
万方数据
维普
